Oak Harvest Investment Services Buys 212 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oak Harvest Investment Services boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,161 shares of the medical equipment provider’s stock after purchasing an additional 212 shares during the period. Oak Harvest Investment Services’ holdings in Intuitive Surgical were worth $2,459,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Norges Bank acquired a new position in Intuitive Surgical in the 4th quarter valued at approximately $1,313,238,000. WCM Investment Management LLC acquired a new position in Intuitive Surgical in the 4th quarter valued at approximately $575,536,000. International Assets Investment Management LLC increased its position in Intuitive Surgical by 32,360.5% in the 4th quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after acquiring an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd increased its position in Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares during the period. Finally, Coatue Management LLC increased its position in Intuitive Surgical by 65.7% in the 4th quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after acquiring an additional 516,054 shares during the period. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ISRG shares. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a “buy” rating and a $500.00 price objective for the company. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Evercore ISI raised their price objective on shares of Intuitive Surgical from $385.00 to $425.00 and gave the stock an “in-line” rating in a report on Tuesday. Piper Sandler raised their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Finally, Jefferies Financial Group raised their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $404.79.

Intuitive Surgical Trading Down 0.9 %

Shares of ISRG traded down $4.00 during mid-day trading on Thursday, reaching $434.81. The company’s stock had a trading volume of 826,374 shares, compared to its average volume of 1,473,994. The stock has a market cap of $154.23 billion, a PE ratio of 78.49, a P/E/G ratio of 5.67 and a beta of 1.39. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $448.10. The company’s fifty day moving average price is $407.60 and its two-hundred day moving average price is $385.43.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.00 EPS. Research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Transactions at Intuitive Surgical

In related news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares in the company, valued at approximately $343,628.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $110,456.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now directly owns 883 shares in the company, valued at $343,628.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,956 shares of company stock worth $6,927,011. 0.80% of the stock is currently owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.